, based on red yeast rice, berberine, policosanol and some antioxidants, for the treatment of dyslipidemic people. MATERIAL AND METHODS: In this open-label trial we treated with this nutraceutical 37 dyslipidemic nondiabetics and 15 dyslipidemic type 2 diabetics for 12 months, monitoring serum lipids, fasting glucose, glycated hemoglobin, blood pressure, and performing also anthropometric measurements including skinfold thickness. RESULTS: Both in dyslipidemic and diabetic patients we observed a great (about 80-100 mg/dL) parallel decrease of total-and non-HDL Cholesterol, not justified by LDL-Ch decrease (about 37 mg/ dL). Furthermore, while body weight and body mass index were not affected significantly by treatment, suprailiac skinfolds (around 6 cm) and total skinfold sum (10 cm) were heavily reduced by the nutraceutical in both groups of patients. CONCLUSION: The present paper confirms that this nutraceutical, due to the synergistic complementary interaction between berberine and red yeast rice, is a reliable option for effective management of dyslipidemia in metabolic disorders with glucolipidic abnormalities.